TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01732497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miraDry Treatment
Description: Application of electromagnetic energy to heat the lower dermis.
Study: NCT02936583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)
Study: NCT02317861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzbromarone
Description: Oral Treatment
Study: NCT03024970

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A lens with solution additive (test)
Description: silicone hydrogel lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A lens with solution additive (test)
Description: silicone hydrogel lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A lens (control)
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A lens (control)
Description: contact lens
Study: NCT03462576

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methacetin Breath Test
Description: A breath analyzer will be used to measure changes in carbon 12 to carbon13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methacetin Breath Test
Description: A breath analyzer will be used to measure changes in carbon 12 to carbon13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Methacetin Breath Test
Description: A breath analyzer will be used to measure changes in carbon 12 to carbon13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emricasan
Description: Investigational drug for NASH treatment in Main Conatus protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emricasan
Description: Investigational drug for NASH treatment in Main Conatus protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo versus emricasan in Conatus NASH treatment trial
Study: NCT03992976

Intervention type: OTHER
Intervention: Online Chronic Pain Management Intervention for Teenagers
Description: The intervention itself is currently under development. This development study is used to gather patient (teenager) insights, as well as insights from parents of these patients, which will inform the content and structure of the proposed intervention. This is done using qualitative-only techniques. Initial ideas for the intervention design mirror current clinical practices in paediatric chronic pain management. There are likely to be several different online modules, which include psychological techniques, medicine (advice), nursing (advice and guidance on non-pharmacological physical pain management), and physiotherapy (guidance for pacing and physiotherapy exercises). The intervention is intended to help teenagers employ a vast range of self-management techniques from these disciplines. Exact content is not yet refined as this is a development study.

Intervention type: OTHER
Intervention: Online Chronic Pain Management Intervention for Teenagers
Description: The intervention itself is currently under development. This development study is used to gather patient (teenager) insights, as well as insights from parents of these patients, which will inform the content and structure of the proposed intervention. This is done using qualitative-only techniques. Initial ideas for the intervention design mirror current clinical practices in paediatric chronic pain management. There are likely to be several different online modules, which include psychological techniques, medicine (advice), nursing (advice and guidance on non-pharmacological physical pain management), and physiotherapy (guidance for pacing and physiotherapy exercises). The intervention is intended to help teenagers employ a vast range of self-management techniques from these disciplines. Exact content is not yet refined as this is a development study.
Study: NCT01921751

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low intensity radiation therapy
Description: 50.4 Gy in 28 1.8 Gy fractions (IMRT or 3D-CRT), 5 days/week, starting 3-5 weeks after the last dose of induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2 PO twice daily, 5 days/week, beginning on the first day of radiation therapy and ending on the last day of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2 PO twice daily, 5 days/week, beginning on the first day of radiation therapy and ending on the last day of radiation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 weekly as a 30 minute infusion after nab-Paclitaxel, three weeks on and 1 week off \[1 cycle = 4 weeks\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 weekly as a 30 minute infusion after nab-Paclitaxel, three weeks on and 1 week off \[1 cycle = 4 weeks\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 weekly as a 30 minute infusion after nab-Paclitaxel, three weeks on and 1 week off \[1 cycle = 4 weeks\]

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high intensity radiation therapy
Description: 63 Gy intensity-modulated radiation therapy (IMRT) in 28 2.25 Gy fractions, 5 days/week, starts 3-5 weeks after the last dose of induction chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: 125 mg/m2 weekly as a 30-40 minute infusion, three weeks on and 1 week \[1 cycle = 4 weeks\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: 125 mg/m2 weekly as a 30-40 minute infusion, three weeks on and 1 week \[1 cycle = 4 weeks\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: 125 mg/m2 weekly as a 30-40 minute infusion, three weeks on and 1 week \[1 cycle = 4 weeks\]
Study: NCT03676621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: buccal tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: intravenous drip
Study: NCT01897285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AQUACEL® foam adhesive dressing
Study: NCT02820792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: function tests
Description: function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: function tests
Description: function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA ProtectorTM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu AuraGainTM
Study: NCT01631136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m²

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250 mg/m²
Study: NCT03917173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery plus HIPEC CO2
Description: Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin v

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgery
Description: Standard surgery without HIPEC CO2
Study: NCT01217632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Study: NCT03302715

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Mucosal tissue sampling
Description: Mucosal tissue sampling for DNA analysis
Study: NCT02498015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D regimen
Description: The 3D regimen contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily for genotype 1b without cirrhosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D regimen with ribavirin
Description: The 3D regimen with ribavirin contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a and genotype 1b with cirrhosis.
Study: NCT00823407

Intervention type: DRUG
Group type: OTHER
Intervention: MDA
Description: subjects will receive a single oral dose of MDA 98mg/70kg body weight

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects will receive a single oral dose of placebo
Study: NCT02921620

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRX-102
Description: Intravenous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study: NCT03394144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150, Durvalumab
Description: After confirmed safety with Cohort 1, Cohort 2 will open. Patients allocated in each cohort will be evaluated for DLT
Study: NCT00502138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Pramlintide infusion
Description: pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses
Study: NCT01479179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: Phase I Starting Dose: 18 mg/kg by vein on Day 1 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Phase I and II Starting Dose: 8 mg/kg by vein on Day 1 of a 21 day cycle.~Phase I and II Maintenance Dose: 6 mg/kg by vein on Day 1 of a 21 day cycle.
Study: NCT02575768

Intervention type: OTHER
Intervention: Adenosine-stress cardiac magnetic resonance imaging
Description: undergoing adenosine-stress cardiac magnetic resonance imaging

Intervention type: OTHER
Intervention: Adenosine-stress cardiac magnetic resonance imaging
Description: undergoing adenosine-stress cardiac magnetic resonance imaging

Intervention type: OTHER
Intervention: Adenosine-stress cardiac magnetic resonance imaging
Description: undergoing adenosine-stress cardiac magnetic resonance imaging
Study: NCT01231100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCUE-guided care
Description: Care directed by hand-carried ultrasound echocardiography
Study: NCT00315744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone
Description: Salmeterol/ fluticasone are a type of long acting beta-agonist (LABA). Salmeterol 50 microgram/ fluticasone 100 microgram combination will be administered to eligible subjects via inhalation route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate is a type of LABA. Fluticasone 100 microgram dose will be administered to eligible subjects via inhalation route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.
Study: NCT04746352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BES-SMFR
Description: For the BES intervention, it was performed using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive. BES was performed once every 2 days for 4 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BES
Description: First, a standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use. Second, patients were required to participate in intensive training regarding myofascial release techniques. Following the training, SMFR was regularly performed by at home for 5 minutes daily for 4 weeks. SMFR was confirmed with patients at all their follow up visits.
Study: NCT01006265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800 Dose 1
Description: ACT-128800 (Dose 1) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800 Dose 2
Description: ACT-128800 (Dose 2) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800 Dose 3
Description: ACT-128800 (Dose 3) administered orally once daily
Study: NCT03789851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: core needle biopsy
Description: Because the ultrasound was unable to accurately position the marker clip, I125 coud be placed at the position of the marker clip under the guidance of preoperative mammography. The gamma detector was used to locate the tumor bed to guide the ultrasound-guided multi-point CNB. Ultrasound-guided multipoint CNB was used directly after breast conserving surgery or mastectomy. Centering on the marker clip, the range of 0.5 cm was the first area, and then the range of 0.5 cm was the second area, and so on, until the extent of the expansion reached the long diameter of the original tumor, and 4 pieces were uniformly taken in each area.
Study: NCT01464437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.
Study: NCT01758796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-operative treatment
Description: Below-the-knee cast for six weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Open reduction and internal fixation with 1/3 semi-tubular plate and screws.
Study: NCT02988570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-evaluation of the language
Description: A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
Study: NCT00951847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxcarbazepine 300 mg/5 mL oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxcarbazepine 300 mg/5 mL oral suspension
Study: NCT04340713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: information support program
Description: According to the established information support program for prostate cancer patients during hormonal therapy, information support and guidance on disease knowledge, symptom management, life care and other aspects are provided to patients through face-to-face communication, telephone, written information, network and other ways.
Study: NCT03702764

Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA
Description: 128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques.

Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA
Description: 128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques.
Study: NCT00006047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral 9-Nitrocamptothecin
Study: NCT03196076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid microsphere
Description: Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid microsphere
Description: Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.
Study: NCT01034735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: r-hGH liquid (Saizen)
Description: Treatment Arm A: r-hGH liquid multidose formulation 5.83 mg/mL, needle injection (0.686 mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: r-hGH liquid (Saizen)
Description: Treatment Arm B: r-hGH liquid multidose formulation 8.0 mg/mL, needle injection (0.5 mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: r-hGH freeze-dried
Description: Treatment Arm C: r-hGH 8 mg (8.8 mg/1.51 ml) freeze-dried formulation ( reconstituted in metacresol 0.3% w/v) needle injection (0.686 mL)
Study: NCT00820495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web + Phone
Description: Web + Phone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Only
Description: Web Only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Only
Description: Phone Only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care
Study: NCT03831971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANS-6637
Description: Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
Study: NCT00912028

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: methafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vifilcon A
Description: contact lens
Study: NCT03653273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DMT withdrawal
Description: Group 1 (DMT withdrawal) will not undergo any disease modifying treatments (DMT).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMT continuation
Description: Group 2 (DMT continuation) may undergo the DMT . The therapy continued in this research is the one previously established, at the same dose, not implying additional precautions for use.